{"type":"trials","record":{"id":39126,"source_id":"clinicaltrials-gov","external_id":"NCT02062099","title":"PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)","brief_summary":"Alzheimer's disease (AD) is the most common cause of dementia in elderly subjects. AD is characterized by brain lesions like extracellular deposits of ß-amyloïd proteins in senile plaques and intracellular neurofibrillary tangles of hyper-phosphorylated tau protein, both of which are associated with the loss of neurons. The development of disease biomarkers for AD (Tau, PhTau and βamyloid dosing in the cerebrospinal fluid, brain MRI, amyloid PET imaging and fluorodeoxyglucose PET imaging) to identify the pathophysiological processes underlying cognitive impairment biomarkers, have been incorporated into revised diagnosis guidelines. Post-mortem human AD and AD animal model studies have reported inflammatory processes also implicated in the neuropathology of AD, and upregulated levels of pro-inflammatory cytokines. In vivo visualization of microglial activation has become possible with the development of molecular imaging ligands (tracers) for use with positron emission tomography (PET). The translocator protein (TSPO) formerly known as the peripheral benzodiazepine receptor (PBR), a receptor located in the outer membrane of mitochondria, is upregulated during neuroinflammation. So targeting TSPO with radiolabeled ligands for PET is considered as an attractive biomarker for neuroinflammation. The main aim of this pilot study is to quantify neuroinflammation, in terms of fixation and distribution of \\[18F\\] DPA-714(Binding Potential BP), and to study its relationship with amyloid load, measured with in \\[18F\\]AV-45 (Standard Uptake Values ratio) in cognitive decline.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"University Hospital, Tours","enrollment":25,"countries":["France"],"start_date":"2014-01-01","completion_date":"2018-05-22","last_update_date":"2022-09-14","source_url":"https://clinicaltrials.gov/study/NCT02062099","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:14.411411+00:00","last_seen_at":"2026-09-25T06:20:07.141+00:00","metadata":{"sex":"ALL","acronym":"NIDeCo","age_range":"60 Years to 80 Years","comparator":null,"organization":"University Hospital, Tours","interventions":["[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Fixation and distribution of [18F]DPA-714 (Binding Potential BP) — 2 years","[18F]AV-45 Standard Uptake Values ratio — 2 years","Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline. — 2 years"],"design_description":"NA · SINGLE GROUP · DIAGNOSTIC · NONE","source_has_results":false},"controlled_terms":["Memory Complaint","Mild Cognitive Impairment","Alzheimer Disease","[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: neuroinflammation.","quality_checked_at":"2026-09-25T06:20:08.679024+00:00","duplicate_cluster_key":"id:nct02062099","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-01-01 to 2018-05-22","comparator":null,"confidence":"structured-source","population":"ALL · 60 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:07.166Z","intervention":["[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment"],"participants":25,"study_design":"NA · SINGLE GROUP · DIAGNOSTIC · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Fixation and distribution of [18F]DPA-714 (Binding Potential BP) — 2 years","[18F]AV-45 Standard Uptake Values ratio — 2 years","Relationship between [18F]DPA-714 uptake and cognitive, affective symptoms at baseline. — 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"neuroinflammation","is_published":true,"match_reasons":["Title contains controlled term: neuroinflammation.","Abstract contains controlled term: neuroinflammation.","Title supplies longevity context: aging.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Neuroinflammation","slug":"neuroinflammation"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/39126","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}